Asthma J45.0 J45.1 J45
Conditions
Interventions
Sponsors
Koordinierungszentrum für Klinische Studien
der Philipps Universität Marburg
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Diagnosis of Asthma according to GINA guidelines - Reversible airway obstruction (FEV1 > 12 % and 200 ml) post 400 µl Salbutamol
Exclusion criteria
Exclusion criteria: - COPD or any other disease of the respiratory system (except athma) - Respiratory tract infections within 30 days before timepoint -1 - Systemic or inhaled corticosteroids within 3 months prior before timepoint -1 - Non-stable phenotype regarding sputum-eosinophilia at timepoint 0 - Beta-blocker - Active smoking or ex-smoking for less than 1 year - Smoking > 1 packyear - Significant diseases other than asthma. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study. - Planned hospitalization during the course of the study - Any clinically relevant abnormal result (lab or clincal) at the timepoints -1 and 0 - Patients who are currently participating in another study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene expression in lymphocytes (Affymetrix HGO 133+2.0 Arrays) | — |
Secondary
| Measure | Time frame |
|---|---|
| FeNO, induced sputum, exhaled breath condensate, electronic nose | — |
Countries
Germany
Contacts
Public ContactTimm Greulich
UKGM Marburg
Outcome results
None listed